This post was originally published on this site
Medtronic announced earnings per share of $1.13 on revenue of $7.37B. Analysts polled by Investing.com anticipated EPS of $1.12 on revenue of $7.22B.
Medtronic shares are down 10% from the beginning of the year, still down 31.50% from its 52 week high of $135.89 set on September 9, 2021. They are outperforming the S&P 500 which is down 13.18% from the start of the year.
Medtronic’s report follows an earnings missed by Eli Lilly on August 4, who reported EPS of $1.25 on revenue of $6.49B, compared to forecasts EPS of $1.7 on revenue of $6.85B.
Pfizer had beat expectations on July 28 with second quarter EPS of $2.04 on revenue of $27.74B, compared to forecast for EPS of $1.72 on revenue of $25.49B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
